BioCardia, Inc.
BCDAHealthcare|Biotechnology|US
$0.85
-0.04 (-4.49%)
DCF Value
$0.21
Tangible Book / Share
$0.22
Cash / Share
$0.34
Clinical Trials (6)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05925608 Clinical Trial of Human Allogenic Culture-expanded Bone Marrow-derived Mesenchymal Stem Cells | Heart Failure, Systolic | P1P2 | Active | 39 | RCT, Double-blind | — |
| NCT06258447 CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction | Ischemic Heart Failure | N/A | Recruiting | 250 | RCT, Double-blind | — |
| NCT03455725 CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial | Refractory Angina, Chronic Myocardial Ischemia | N/A | Active | 343 | RCT, Double-blind | — |
| NCT02438306 CardiAMP™ Cell Therapy for Heart Failure Trial | Heart Failure, Systolic | P3 | Completed | 125 | RCT, Double-blind | Autologous cell therapy |
| NCT00507468 Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone | Ventricular Dysfunction, Myocardial Infarction | P1 | Completed | 20 | Open-label | — |
| NCT05491681 AllogeneiC Expanded Human MSC Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial | ARDS, Human | P1 | Withdrawn | — | Open-label | intravenous delivery of allogeneic bone marrow-derived MSCs |